Hannam & Partners, a leading independent investment bank, issued an independent research report on Psyence Group.

The report identifies the company as a first mover into the palliative care market supported by natural psilocybin production.

It notes that while Psyence has already generated revenue through its functional mushroom joint venture (Psyence Function) and production facility vertical (Psyence Production), it attributes the lion’s share of Psyence’s value to its drug discovery programme and expects a 450 per cent uplift in share price.

Psyence Group Inc. (PSYG) opened trading at C$0.10

More From The Market Herald

" @ the Bell: TSX snaps six-day selloff

A day after posting its longest streak of daily declines since May, Canada’s main stock index rose on Wednesday led by precious metal

" Satellos Bioscience (TSXV:MSCL) appoints new Chief Technology Officer

Satellos Bioscience (MSCL) has appointed Philip Lambert, Ph.D., as Chief Technology Officer of the company, effective September 27, 2022.

" VitalHub (TSX:VHI) announces multi year contract with NHS Mid and South Essex ICB

VitalHub (VHI) announced a multi-year licensing contract with NHS Mid and South Essex Integrated Care Board (Essex).

" Silvercorp Metals Inc. Confirms Its Golden Potential with a Reserve and Resource Update

By Dr. Ryan D. Long